Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors.

Immunotherapy · 2020 · PMC7273903 · PMID 32489118

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a favorable trendp = 0.08so close (0.05 < p ≤ 0.1)

At the first interim analysis, there was also a favorable trend in overall survival (OS) (21.3 vs 17.6 months; p = 0.08), which became significant in the PD-L1-positive subgroup in favor of the experimental arm (25.0 vs 15.5 months) [ 14 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.